Eriodictyol

Eriodictyol

SCHEMBL2309591

O=C1CC(c2ccc(O)c(O)c2)Oc2cc(O)cc(O)c21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 8/20 1.00
CYP3A4 P08684 6/20 1.00
CYP1A1 P04798 6/20 1.00
CYP1A2 P05177 6/20 1.00
CYP1B1 Q16678 6/20 1.00
CYP2C19 P33261 4/20 1.00
HSD17B10 Q99714 4/20 1.00
CA12 O43570 3/20 1.00
CA4 P22748 3/20 1.00
CA7 P43166 3/20 1.00
TP53 P04637 3/20 1.00
MAPT P10636 3/20 1.00
SLCO2B1 O94956 2/20 1.00
PSMB5 P28074 2/20 1.00
ALDH1A1 P00352 2/20 1.00
POLB P06746 2/20 1.00
PKM P14618 2/20 1.00
HPGD P15428 2/20 1.00
MAPK1 P28482 2/20 1.00
RPS6KA3 P51812 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Eriodictyol SCHEMBL19180 1.00 CYP19A1 (1.00) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1
Eriodictyol SCHEMBL29709569 1.00 CYP19A1 (1.00) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1
Eriodictyol SCHEMBL29382523 1.00 CYP19A1 (1.00) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1
Eriodictyol SCHEMBL30468822 1.00 CYP19A1 (1.00) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1
Eriodictyol SCHEMBL29603762 1.00 CYP19A1 (1.00) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1
Eriodictyol SCHEMBL23686074 1.00 CYP19A1 (1.00) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1
Eriodictyol SCHEMBL29378971 1.00 CYP19A1 (1.00) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1
Naringenin SCHEMBL1048136 0.89 CYP19A1 (1.00) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1
Naringenin SCHEMBL20570 0.89 CYP19A1 (1.00) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1
Naringenin SCHEMBL20571 0.89 CYP19A1 (1.00) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 312 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210290514-A1 An Antimicrobial Combination Composition Comprising Glycerol Derivatives and Bicyclic Compounds SACHEM EUROPE B.V. (NL) 2021-09-23 US claimed
CN-112955113-A Antimicrobial binding compositions comprising glycerol derivatives and bicyclic compounds 科莱恩国际有限公司 2021-06-11 CN claimed
EP-3817712-A1 AN ANTIMICROBIAL COMBINATION COMPOSITION COMPRISING GLYCEROL DERIVATIVES AND BICYCLIC COMPOUNDS Clariant International Ltd (CH) 2021-05-12 EP claimed
WO-2020007571-A1 AN ANTIMICROBIAL COMBINATION COMPOSITION COMPRISING GLYCEROL DERIVATIVES AND BICYCLIC COMPOUNDS CLARIANT INTERNATIONAL LTD (CH) 2020-01-09 WO claimed
EP-1258200-B1 Use of hydroxyflavones for masking of bitterness, and food and pharmaceutical compositions comprising an effective amount thereof SYMRISE GMBH & CO KG (DE) 2005-02-16 EP claimed
US-20020188019-A1 Use of hydroxyflavanones for masking bitter taste SYMRISE AG (DE) 2002-12-12 US claimed
EP-1258200-A2 Use of hydroxyflavones for masking of bitterness, and food and pharmaceutical compositions comprising an effective amount thereof HAARMANN & REIMER GMBH (DE) 2002-11-20 EP claimed
US-4617293-A Flavonoid phosphate salts of aminoglycoside antibiotics MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 1986-10-14 US claimed
JP-62145016-A None JP disclosed
EP-4746880-A2 METHODS OF TREATING DILATED CARDIOMYOPATHY Regencor, Inc. (US) 2026-05-27 EP disclosed
EP-3723723-B1 EXTRACT OF THE AERIAL PARTS OF LAWSONIA INERMIS AND ITS PREPARATION METHOD PIERRE FABRE DERMO COSMETIQUE (FR) 2026-03-18 EP disclosed
EP-4699452-A2 OBTAINING A VOLATILE FRACTION FROM JUICES OR ALCOHOLIC BEVERAGES Symrise AG (DE) 2026-02-25 EP disclosed
US-20260041109-A1 ROBUST FLAVOR EMULSIONS INT FLAVORS & FRAGRANCES INC (US) 2026-02-12 US disclosed
EP-3836799-B1 OBTAINING A VOLATILE FRACTION FROM JUICES OR ALCOHOLIC BEVERAGES SYMRISE AG (DE) 2025-11-26 EP disclosed
US-5229113-A Gene expression, soybeans LUBRIZOL GENETICS, INC. (US) 1993-07-20 US disclosed
US-5023180-A Bradyrhizobium japonicum nodulation regulatory protein and gene LUBRIZOL GENETICS, INC. (US) 1991-06-11 US disclosed
JP-S62145016-A ANTIBACTERIAL AGENT MITSUBISHI CHEM IND LTD 1987-06-29 JP disclosed
US-4617293-A Flavonoid phosphate salts of aminoglycoside antibiotics MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 1986-10-14 US disclosed
EP-0065123-B1 HARDLY SOLUBLE SALTS OF AMINOGLYCOSIDE ANTIBIOTICS MERCK PATENT GmbH (DE) 1984-07-25 EP disclosed
EP-0065123-A1 Hardly soluble salts of aminoglycoside antibiotics MERCK PATENT GmbH (DE) 1982-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210290514-A1 An Antimicrobial Combination Composition Comprising Glycerol Derivatives and Bicyclic Compounds GK, MGLL, UGCG CYP19A1 1248/4885CYP3A4 2337/4885CYP1A1 2314/4885
US-20020188019-A1 Use of hydroxyflavanones for masking bitter taste TAS2R60, TAS2R50, TAS2R30 CYP19A1 3365/4885CYP3A4 582/4885CYP1A1 1504/4885
US-20260041109-A1 ROBUST FLAVOR EMULSIONS ACACA, FABP4, CUTA CYP19A1 1948/4885CYP3A4 4033/4885CYP1A1 2995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.